<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503516</url>
  </required_header>
  <id_info>
    <org_study_id>BO-EC-DEM-02</org_study_id>
    <secondary_id>EudraCT number:2006-005759-13</secondary_id>
    <nct_id>NCT00503516</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients</brief_title>
  <official_title>Multicenter, Double Blind, Randomized, Clinical Trial, Controlled With Placebo, to Evaluate the Effect of the Treatment With 320 mg/Day of Megestrol Acetate During 24 Weeks in the Weight Loss in Mixed Dementia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rottapharm Spain</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rottapharm Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy of megestrol acetate in the gain of
      body weight in patients with primary or mixed Dementia with a weight loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In all geriatric patients with dementia it was prove a weight loss independently if they are
      institutionalized or not.There are some previous studies that indicates the effect of the
      megestrol acetate in the weight gain of patients with cachexia-anorexia related with
      neoplasia. It seems that the mechanism of development could be the same between these
      patients and patients with dementia. It was described an important role of a group of
      cytokines ( Il-6, leptin, neuropeptide Y, TNFalfa) in the development of this nutritional
      alteration.

      Some previous pilots studies indicates that megestrol acetate has and effect in geriatric and
      dementia patients with a weight loss of at least 5% in the last 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties to recruit the patients following the inclusion criteria
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the change in the body weight</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change in the appetite</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change in biochemical markers: Il-6, Il-1, leptin, TNFalfa, neuropeptide Y, albumin and prealbumin</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the change in the nutritional status (Mini-Nutritional Assessment)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change in cognitive state ( Mini-Mental State Examination)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of the treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol acetate 160 mg b.i.d. during 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 sachet of powder of placebo b.i.d. during 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate</intervention_name>
    <description>1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 sachet of 160 mg of placebo b.i.d.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed of primary or mixed dementia (CIE 10criteria)

          -  Weihgt loss &gt;5% of habitual weight in the last 6 months and proteic-caloric
             malnutrition (MNA &lt;17)

          -  Outpatients

          -  Patients that accept the participation in the study

        Exclusion Criteria:

          -  Vascular pure Dementia and secondary dementias( vascular dementia, Parkinson
             disease,etc)

          -  Dementia in a terminal phase: category of FAST 7c in the Reisber scale

          -  Concomitant treatment with steroids, androgens or other drugs with progestagens

          -  Weight loss secondary to neoplasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pau Sánchez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Socio Sanitario del Hospitalet (Barcelona)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvador Altimir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Germans Trias i Pujol (Badalona)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramón Cristófol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antic Hospital Sant Jaume i Santa Magdalena (Mataró)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Sabartés, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique Arriola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Matia (San Sebastián)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis González, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Nuestra Señora de la Montaña (Cáceres)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esher Martínez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de la Santa Creu (Tortosa)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Petidier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Getafe (Madrid)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esperanza Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen del Valle (Toledo)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Almudena Garnica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari San Joan de Reus (Tarragona)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Regina Feijoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. Sta. Caterina Gerona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Tantiña, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAP Centelles (Barcelona)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Socio Sanitario del Hospitalet</name>
      <address>
        <city>El Hospitalet</city>
        <state>Barcelona</state>
        <zip>08906</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2007</study_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Anna Anguera, Research Manager</name_title>
    <organization>Madaus, S.A.</organization>
  </responsible_party>
  <keyword>weight loss, appetite, dementia, megestrol acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

